{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:28:17Z","timestamp":1793734097029,"version":"4.6.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40290-022-00428-w","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T19:14:52Z","timestamp":1654629292000},"page":"163-171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5929-0466","authenticated-orcid":false,"given":"Ajeet","family":"Gajra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-6513","authenticated-orcid":false,"given":"Abigail","family":"Zalenski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Sannareddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1711-849X","authenticated-orcid":false,"given":"Yolaine","family":"Jeune-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1577-4917","authenticated-orcid":false,"given":"Kandice","family":"Kapinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6901-0782","authenticated-orcid":false,"given":"Ankit","family":"Kansagra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"issue":"5","key":"428_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"26","key":"428_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"5","key":"428_CR3","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.apsb.2020.10.020","volume":"11","author":"H Dana","year":"2021","unstructured":"Dana H, Chalbatani GM, Jalali SA, Mirzaei HR, Grupp SA, Suarez ER, et al. CAR-T cells: early successes in blood cancer and challenges in solid tumors. Acta Pharm Sin B. 2021;11(5):1129\u201347.","journal-title":"Acta Pharm Sin B"},{"issue":"4","key":"428_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2217\/cer.15.27","volume":"4","author":"DE Gerber","year":"2015","unstructured":"Gerber DE, Pruitt SL, Halm EA. Should criteria for inclusion in cancer clinical trials be expanded? J Comp Eff Res. 2015;4(4):289\u201391.","journal-title":"J Comp Eff Res"},{"issue":"3","key":"428_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.36401\/JIPO-21-2","volume":"4","author":"LJN Kevin Tang","year":"2021","unstructured":"Kevin Tang LJN. Real-world experiences of CAR T-cell therapy for large B-cell lymphoma: how similar are they to the prospective studies? J Immunother Precis Oncol. 2021;4(3):150\u20139.","journal-title":"J Immunother Precis Oncol"},{"issue":"Supplement_1","key":"428_CR6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1182\/blood-2019-124364","volume":"134","author":"KM Kilgore","year":"2019","unstructured":"Kilgore KM, Mohammadi I, Schroeder A, Teigland C, Purdum A, Shah GL. Medicare patients receiving chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma: a first real-world look at patient characteristics, healthcare utilization, and costs. Blood. 2019;134(Supplement_1):793.","journal-title":"Blood"},{"issue":"Supplement_1","key":"428_CR7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1182\/blood-2018-99-117199","volume":"132","author":"C Jacobson","year":"2018","unstructured":"Jacobson C, Hunter B, Armand P, Kamihara Y, Ritz J, Rodig S, et al. Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity. Blood. 2018;132(Supplement_1):92.","journal-title":"Blood"},{"issue":"4","key":"428_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2072","volume":"3","author":"GH Lyman","year":"2020","unstructured":"Lyman GH, Nguyen A, Synder S. Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma. JAMA Netw Open. 2020;3(4): e202072.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"428_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002056","volume":"9","author":"GD Myers","year":"2021","unstructured":"Myers GD, Verneris MR, Goy A, Maziarz RT. Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia. J Immunother Cancer. 2021;9(4): e002056.","journal-title":"J Immunother Cancer"},{"key":"428_CR10","unstructured":"Dearment A. Outpatient use of CAR-Ts is enticing, but it comes with significant challenges too. 2020 June 3, 2020. https:\/\/medcitynews.com\/2020\/06\/outpatient-use-of-car-ts-is-enticing-but-it-comes-with-significant-challenges-too\/. Accessed 8 Mar 2022."},{"issue":"Supplement_1","key":"428_CR11","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1182\/blood-2019-127566","volume":"134","author":"CR Bachier","year":"2019","unstructured":"Bachier CR, Palomba ML, Abramson JS, Andreadis C, Sehgal AR, Godwin J, et al. Outpatient treatment with lisocabtagene maraleucel (liso-cel) in three ongoing clinical studies in relapsed\/refractory (r\/r) B cell non-Hodgkin lymphoma (NHL), including second-line transplant ineligible patients: transcend NHL 001, Outreach, and PILOT. Blood. 2019;134(Supplement_1):2868.","journal-title":"Blood"},{"issue":"Supplement 1","key":"428_CR12","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/blood-2018-99-115252","volume":"132","author":"SJ Schuster","year":"2018","unstructured":"Schuster SJ, Bishop MR, Tam C, Borchmann P, Jaeger U, Waller EK, et al. Sustained disease control for adult patients with relapsed or refractory diffuse large B-cell lymphoma: an updated analysis of Juliet, a global pivotal phase 2 trial of tisagenlecleucel. Blood. 2018;132(Supplement 1):1684.","journal-title":"Blood"},{"issue":"12","key":"428_CR13","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","volume":"25","author":"T Jain","year":"2019","unstructured":"Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, et al. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-hodgkin lymphoma: an expert panel opinion from the American society for transplantation and cellular therapy. Biol Blood Marrow Transplant. 2019;25(12):2305\u201321.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"428_CR14","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1016\/j.bbmt.2018.12.068","volume":"25","author":"AJ Kansagra","year":"2019","unstructured":"Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, et al. Clinical utilization of chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia: an expert opinion from the European society for blood and marrow transplantation and the American society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2019;25(3):e76\u201385.","journal-title":"Biol Blood Marrow Transplant"},{"key":"428_CR15","unstructured":"Caffrey M. Delays With Payers Mean Some Patients Miss Window for CAR T-Cell Therapy, Findings Show. 2021 April 26, 2021. https:\/\/www.ajmc.com\/view\/delays-with-payers-mean-some-patients-miss-window-for-car-t-cell-therapy-findings-show. Accessed 8 Mar 2022."},{"key":"428_CR16","unstructured":"Nam S, Smith J, Yang G. Driving the Next Wave of Innovation in CAR T-cell Therapies. 2019 Dec. 13, 2019. https:\/\/www.mckinsey.com\/industries\/life-sciences\/our-insights\/driving-the-next-wave-of-innovation-in-car-t-cell-therapies. Accessed 8 Mar 2022."},{"issue":"3","key":"428_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. \u201cOff-the-shelf\u201d allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185\u201399.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"428_CR18","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"10297","key":"428_CR19","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"issue":"4","key":"428_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"issue":"26","key":"428_CR21","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321\u201330.","journal-title":"Blood"},{"key":"428_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355.","journal-title":"Blood Rev"},{"issue":"18","key":"428_CR23","doi-asserted-by":"publisher","first-page":"4823","DOI":"10.1158\/1078-0432.CCR-20-1434","volume":"26","author":"R Faramand","year":"2020","unstructured":"Faramand R, Jain M, Staedtke V, Kotani H, Bai R, Reid K, et al. Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel. Clin Cancer Res. 2020;26(18):4823\u201331.","journal-title":"Clin Cancer Res"},{"key":"428_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/ITT.S202015","volume":"8","author":"H Murthy","year":"2019","unstructured":"Murthy H, Iqbal M, Chavez JC, Kharfan-Dabaja MA. Cytokine release syndrome: current perspectives. Immunotargets Ther. 2019;8:43\u201352.","journal-title":"Immunotargets Ther"},{"issue":"6","key":"428_CR25","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/17474086.2016.1183479","volume":"9","author":"M Namuduri","year":"2016","unstructured":"Namuduri M, Brentjens RJ. Medical management of side effects related to CAR T cell therapy in hematologic malignancies. Expert Rev Hematol. 2016;9(6):511\u20133.","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"428_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"428_CR27","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41587-019-0403-9","volume":"38","author":"G Giordano-Attianese","year":"2020","unstructured":"Giordano-Attianese G, Gainza P, Gray-Gaillard E, Cribioli E, Shui S, Kim S, et al. A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy. Nat Biotechnol. 2020;38(4):426\u201332.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"428_CR28","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJMc2030164","volume":"384","author":"EA Chong","year":"2021","unstructured":"Chong EA, Ruella M, Schuster SJ. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. N Engl J Med. 2021;384(7):673\u20134.","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"428_CR29","first-page":"40","volume":"136","author":"C Jacobson","year":"2020","unstructured":"Jacobson C, Locke FL, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term survival and gradual recovery of B cells in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel). Blood. 2020;136(Supplement_1):40\u20132.","journal-title":"Blood"},{"key":"428_CR30","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","volume":"10","author":"X Xu","year":"2019","unstructured":"Xu X, Qihang S, Liang X, Chen Z, Zhang X, Zhou X, et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019;10:2664.","journal-title":"Front Immunol"},{"issue":"22","key":"428_CR31","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D\u2019Aveni-Piney M, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(22):5607\u201315.","journal-title":"Blood Adv"},{"key":"428_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40364-020-00197-1","volume":"8","author":"Y Nie","year":"2020","unstructured":"Nie Y, Weiqing L, Chen D, Tu H, Guo Z, Zhou X, et al. Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies. Biomark Res. 2020;8:18.","journal-title":"Biomark Res"},{"issue":"Supplement_1","key":"428_CR33","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1182\/blood-2021-148078","volume":"138","author":"C Jacobson","year":"2021","unstructured":"Jacobson C, Locke F, Ghobadi A, et al. Long-term (4- and 5-year) overall survival in ZUMA-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients with refractory large B-cell lymphoma (LBCL). Blood. 2021;138(Supplement_1):1764.","journal-title":"Blood"},{"key":"428_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40364-020-00197-1","volume":"8","author":"Y Nie","year":"2020","unstructured":"Nie Y, Weiqing L, Chen D, et al. Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies. Biomark Res. 2020;8:18.","journal-title":"Biomark Res."},{"issue":"10254","key":"428_CR35","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352.","journal-title":"Lancet"},{"issue":"14","key":"428_CR36","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342.","journal-title":"N Engl J Med"},{"issue":"10299","key":"428_CR37","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491\u2013502.","journal-title":"Lancet"},{"issue":"1","key":"428_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2020009098","volume":"138","author":"BD Shah","year":"2021","unstructured":"Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021;138(1):11\u201322.","journal-title":"Blood"},{"key":"428_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6004\/jnccn.2021.7033","volume":"19","author":"PC Johnson","year":"2021","unstructured":"Johnson PC, Jacobson C, Yi A, Saucier A, Dhawale TM, Nelson A, et al. Healthcare utilization and end-of-life outcomes in patients receiving CAR T-cell therapy. J Natl Compr Canc Netw. 2021;19:1\u20137.","journal-title":"J Natl Compr Canc Netw"},{"issue":"Supplement_1","key":"428_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2020-134735","volume":"136","author":"A Purdum","year":"2020","unstructured":"Purdum A, Johnson J, Bonagura A, Nyamutswa L, Elliot C, Lal LS. The first retrospective commercial claims-based analysis of CAR T treated patients with relapsed or refractory large B-cell lymphoma (R\/R LBCL). Blood. 2020;136(Supplement_1):31.","journal-title":"Blood"},{"key":"428_CR41","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1200\/JCO.2020.38.29_suppl.76","volume":"38","author":"S Keating","year":"2020","unstructured":"Keating S, Gu T, Jun MP, Pelletier C, McBride A. Health care resource utilization (HCRU) and total costs of care (TCOC) among patients (pts) with diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor (CAR) T-cell therapies in the United States: an analysis of four claims databases. J Clin Oncol. 2020;38:76.","journal-title":"J Clin Oncol"},{"issue":"29_suppl","key":"428_CR42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1200\/JCO.2020.38.29_suppl.61","volume":"38","author":"P Hari","year":"2020","unstructured":"Hari P, Nguyen A, Pelletier C, McGarvey N, Gitlin M, Parikh K. Healthcare resource utilization and cost of cytokine release syndrome and neurotoxicity in patients with relapsed and refractory multiple myeloma receiving the BCMA-directed chimeric antigen receptor T cell therapy idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa trial. J Clin Oncol. 2020;38(29_suppl):61.","journal-title":"J Clin Oncol"},{"key":"428_CR43","unstructured":"Starr, P. Real-World Healthcare Utilization and Costs Support Broader Use of CAR T-Cell Therapy. 2020 Feb. https:\/\/www.ahdbonline.com\/issues\/2020\/february-2020-vol-13-special-issue\/2921-real-world-healthcare-utilization-and-costs-support-broader-use-of-car-t-cell-therapy. Accessed 10 Mar 2022."},{"issue":"7","key":"428_CR44","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/jnci\/djy193","volume":"111","author":"RR Sarkar","year":"2019","unstructured":"Sarkar RR, Gloude NJ, Schiff D, Murphy JD. Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia. J Natl Cancer Inst. 2019;111(7):719\u201326.","journal-title":"J Natl Cancer Inst"},{"issue":"32","key":"428_CR45","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1200\/JCO.2018.79.0642","volume":"36","author":"JK Lin","year":"2018","unstructured":"Lin JK, Lerman BJ, Barnes JI, Boursiquot BC, Tan YJ, Robinson AQ, et al. Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. J Clin Oncol. 2018;36(32):3192\u2013202.","journal-title":"J Clin Oncol"},{"issue":"12","key":"428_CR46","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/jamapediatrics.2018.2530","volume":"172","author":"MD Whittington","year":"2018","unstructured":"Whittington MD, McQueen RB, Ollendorf DA, Kuman VM, Chapman RH, Tice JA, et al. Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia. JAMA Pediatr. 2018;172(12):1161\u20138.","journal-title":"JAMA Pediatr"},{"issue":"24","key":"428_CR47","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.18.02079","volume":"37","author":"JK Lin","year":"2019","unstructured":"Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert A. Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. J Clin Oncol. 2019;37(24):2105\u201319.","journal-title":"J Clin Oncol"},{"issue":"12","key":"428_CR48","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1080\/13696998.2018.1529674","volume":"21","author":"JA Roth","year":"2018","unstructured":"Roth JA, Sullivan SD, Lin VW, Bansal A, Purdum AG, Navale L, et al. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ. 2018;21(12):1238\u201345.","journal-title":"J Med Econ"},{"issue":"2","key":"428_CR49","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0035","volume":"2","author":"MD Whittington","year":"2019","unstructured":"Whittington MD, McQueen RB, Ollendorf DA, Kuman VM, Chapman RH, Tice JA, et al. Long-term survival and cost-effectiveness associated with axicabtagene ciloleucel vs chemotherapy for treatment of B-cell lymphoma. JAMA Netw Open. 2019;2(2): e190035.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"428_CR50","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"F Locke","year":"2022","unstructured":"Locke F, Miklos DB, Jacobson C, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640\u201354.","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"428_CR51","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1182\/blood-2021-147913","volume":"138","author":"M Kamdar","year":"2021","unstructured":"Kamdar M, Solomon SR, Arnason JE, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 transform study. Blood. 2021;138(Supplement_1):91.","journal-title":"Blood"},{"issue":"2","key":"428_CR52","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1182\/bloodadvances.2020001792","volume":"5","author":"M Subklewe","year":"2021","unstructured":"Subklewe M. BiTEs better than CAR T cells. Blood Adv. 2021;5(2):607\u201312.","journal-title":"Blood Adv"},{"issue":"4","key":"428_CR53","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/14712598.2021.1884677","volume":"21","author":"G Salles","year":"2021","unstructured":"Salles G, Dlugosz-Danecka M, Ghesquieres H, Jurczak W. Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Expert Opin Biol Ther. 2021;21(4):455\u201363.","journal-title":"Expert Opin Biol Ther"},{"key":"428_CR54","unstructured":"Staines R. Incyte\/Morphosys take on CAR-Ts with $198,000 per year antibody. 2020. https:\/\/pharmaphorum.com\/news\/incyte-morphosys-take-on-car-ts-as-lymphoma-antibody-monjuvi-approved-in-us\/. Accessed 10 Mar 2022."},{"key":"428_CR55","first-page":"1","volume":"40","author":"A Kansagra","year":"2020","unstructured":"Kansagra A, Farnia S, Majhail N. Expanding access to chimeric antigen receptor T-cell therapies: challenges and opportunities. Am Soc Clin Oncol Educ Book. 2020;40:1\u20138.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"428_CR56","unstructured":"ASCO. CAR-T Therapy Policy Brief Update, in ASCO Position Statement\u2014On Addressing the Affordability of Cancer Drugs. 2017. https:\/\/www.asco.org\/sites\/new-www.asco.org\/files\/content-files\/advocacy-and-policy\/documents\/2017-ASCO-Position-Statement-Affordability-Cancer-Drugs-footer.pdf. Accessed 10 Mar 2022."},{"issue":"4","key":"428_CR57","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s11899-021-00635-3","volume":"16","author":"PR Geethakumari","year":"2021","unstructured":"Geethakumari PR, Ramasamy DP, Dholaria B, Berdeja J, Kansagra A. Balancing quality, cost, and access during delivery of newer cellular and immunotherapy treatments. Curr Hematol Malig Rep. 2021;16(4):345\u201356.","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-022-00428-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-022-00428-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-022-00428-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T08:15:17Z","timestamp":1655885717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-022-00428-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["428"],"URL":"https:\/\/doi.org\/10.1007\/s40290-022-00428-w","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"1 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access publication was funded by\u00a0Cardinal Health. No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ajeet Gajra is a Cardinal Health employee, owns Cardinal Health stock, and is an employee of ICON Clinical Research. Abigail Zalenski is a Cardinal Health employee. Yolaine Jeune-Smith is a Cardinal Health employee and owns Cardinal Health stock. Ankit Kansagra is on the advisory board for AbbVie, Alynylam<sup>\u00ae<\/sup> Pharmaceuticals, Bristol Myers Squibb, Cota Healthcare, GlaxoSmithKline, Janssen Pharmaceuticals, Oncopeptides, and Takeda. Aishwarya Sannareddy and Kandice Kapinos declare that they have no conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All of the authors (AG, AAZ, AS, YJS, KK, and AK) participated in writing and review of the manuscript. AG and AK were responsible for conceptualization of the manuscript. All authors have read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}